Clinical Trial Update: Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a study of BAL101553 given as 48-hour infusions in adults with advanced solid tumors or recurrent glioblastoma has completed testing with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Glioblastoma
• Neoplasms
• Solid Tumors

Drugs mentioned

• BAL101553

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-11